Produtividade e valor nutritivo da Brachiaria brizantha cv. Marandu em um sistema silvipastoril Productivity and nutritional value of Brachiaria brizantha cv. Marandu in a silvopastoral system

O experimento foi realizado em sistema silvipastoril (Ssp) localizado no bioma de Cerrado, no município de Lagoa Santa, Minas Gerais, no ano agrícola de 2004-2005. Avaliou-se a influência do Ssp composto pela arbórea bolsa-de-pastor (Zeyheria tuberculosa) sobre os parâmetros produção, atributos morfogênicos, composição bromatológica e valor nutritivo da gramínea Brachiaria brizantha cv. Marandu, e os efeitos sobre as condições microclimáticas. O delineamento experimental foi em blocos ao acaso, com cinco blocos (épocas de corte), dois tratamentos (T1 - B. brizantha cv. Marandu sombreada com a Z. tuberculosa e T2 - B. brizantha cv. Marandu, a pleno sol) e três repetições (parcelas). O sombreamento proporcionado pela Z. tuberculosa, apesar de reduzir a produção de matéria seca (MS) da gramínea, favoreceu o aumento do teor de proteina bruta (PB) e não alterou a produção de PB/ha e nem afetou a concentração de FDN. Os teores de FDA foram mais altos que os encontrados a pleno sol, o que provavelmente resultou em menor degradabilidade in vitro da MS e da matéria orgânica, não alterando a degradabilidade efetiva.<br>The experiment was carried out in a Silvopastoral system (Sps) located in Brazilian Savannah, Lagoa Santa county, Minas Gerais State, during the agricultural year of 2004-2005. It was studied the influence of Sps formed by "Bolsa de Pastor" (Zeyheria tuberculosa) on the production, morphogenic attributes, bromatological composition and nutritional value of the graminaceous Brachiaria brizantha cv. Marandu as well as on the microclimatic aspects. The Sps was established in 1982, in a red-yellow latossol by the natural regeneration process. The experiment was based on a randomized block design, with 5 blocks (cutting times), 2 treatments (T1 - B. brizantha cv. Marandu shaded by Z. tuberculosa and T2 - B. brizantha cv. Marandu at open sky and three repetitions (plots). Although the DM production of the graminaceous in the Sps with Z. tuberculosa has reduced the level of crude protein (CP) has increased and the production of CP per ha and the Sps NDF concentration have remained unchanged. However, the levels of ADF were higher in the shaded area, which probably resulted in lower in vitro DM and organic matter degradability, but similar effective DM degradability

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores &gt;2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores &gt;2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score &gt;2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores &gt;2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores &gt;2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007. © 2020 Hellenic Society of Cardiolog

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores &gt;2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores &gt;2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and 651 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score &gt;2 and 64 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores &gt;2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores &gt;2 and 27.5% in those with scores 642. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007